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Background: Management of patients with inherited bleeding disorders has improved since the intro-
duction of Comprehensive Care Centres (CCC) in the United Kingdom (UK). In the event such patients
need surgery, the aim of the multidisciplinary team is to facilitate outcomes as good as what would be
expected in a non-bleeding disorder patient. A review of such comprehensive care was carried out in
patients with inherited bleeding disorders when they needed surgery at Northern Ireland CCC. Aims of
the study were to evaluate surgical morbidity and mortality in these patients.
Methods: All patients with inherited bleeding disorders who underwent non-orthopaedic surgery
between 2008 and 2012 were identiﬁed from the CCC records within the Belfast Health and Social Care
Trust (BHSCT) in Northern Ireland (NI) and their case records reviewed.
Results: 28 patients received elective and emergency surgery during this period. There was minimum
morbidity and no mortality in this cohort.
Conclusions: Surgery in patients with inherited bleeding disorders has become safe with the advent of
multidisciplinary CCCs. Close communication between surgeon and haematologist is key in the
successful management of these complex patients.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Surgery in patients with inherited bleeding disorders is tradi-
tionally considered high risk.1,2 However, the establishment of
Comprehensive Care Centres (CCC) in the UK for the management
of inherited bleeding disorders has led to considerably improved
outcomes.3
Inherited bleeding disorders are rare and complex, mainly
comprising of haemophilia and Von Willebrand Disease (VWD).
Haemophilia is a life-long condition that is potentially debilitating,
but a child with haemophilia born today can envisage a normal life
expectancy and a good quality of life due to the availability of effective
treatment in the form replacement therapy with recombinant or; UK, United Kingdom; NI,
e trust; NSAIDs, non-steroidal
is; VTE, venous thromboem-
V, human immunodeﬁciency
a centre.
ospital, Grosvenor Road, Bel-
mad).
ciates Ltd. Published by Elsevier Ltplasma-derived clotting factors.4 There are two main forms of hae-
mophilia: haemophilia A (average incidence 1:5000 males) and hae-
mophilia B (average incidence 1:25000 males). Whilst the advent of
effective and safe prophylaxis has reduced long term joint disease for
those with the more severe form, delaying the need for orthopaedic
surgery,5 it has not altered the need for general surgical interventions.
VWD, despite being more common, is generally considered a milder
bleeding disorder affecting both males and females with average
incidence of 1:1000. Although, severe VWD (type 3) can be a more
signiﬁcantbleedingdisorder thanmildHaemophiliaA.Otherclinically
important inherited bleeding disorders include deﬁciencies of coag-
ulation factors V, X, and XI and platelet disorders.6
Inherited bleeding disorders require wide-ranging care and effec-
tivemanagementwithinamultidisciplinary teamsetting. Themodern
treatments of inherited bleeding disorders are now remarkably
effective and, although expensive, their provisionwith high standards
has been made possible by the development of Comprehensive Care
Centres (CCC) across the UK.7 The Haemophilia Alliance is a Uni-
ted Kingdom wide partnership between patients with inherited
bleeding disorders and healthcare professionals involved in the
delivery of haemophilia care. The Alliance produced “National Serviced. All rights reserved.
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ders” in2001whichwasupdated in2006.8 Theaimof theseguidelines
was to provide a consistently high quality and comprehensive care for
haemophilia patients across the UK. The service speciﬁcations have
recommended that a CCC must have the provision of a general and
specialist surgeon in order tomanage these patientswith very special
needs. Surgery in patients with inherited bleeding disorders is
complex and these procedures should be performed at a regional
centre with expertise and provision of a multidisciplinary team.
There are 280 adult patients registered with inherited
bleeding disorders in the relatively stable population of NI
(Table 1), not including known carriers, in contrast to only 43
reported in 1959.9 This ﬁve-fold increase in registered cases is
most likely a result of improved detection and registration rather
than actual increase in incidence. A brief comparison of historical
and current management of haemophilia and related disorders is
given in Table 2.10,11
Comprehensive care for these patients takes place via the
BHSCT. Whilst the CCC is based at the Belfast City Hospital, surgery
is spread across the three acute hospital sites; Belfast City
Hospital, Royal Victoria Hospital, Mater Hospital and elective
orthopaedic surgery at Musgrave Park Hospital. Patients are
referred to speciﬁc consultant surgical teams to ensure an
expertise can be developed rather than many consultant teams
seeing very few patients. General surgical procedures can be
performed with low morbidity and mortality when there is
appropriate factor replacement and good support from the hae-
matology team.12
We present our experience of NI CCC, with speciﬁc emphasis on
the management of these patients when they need general surgery
(orthopaedic and endoscopic procedures excluded). A close
collaboration and team work between the surgeon and haematol-
ogist is the key towards an optimum outcome for these patients.
The aim of this review was to evaluate morbidity and mortality
associated with general surgical procedures in adult inherited
bleeding disorders patients managed within NI CCC.
2. Materials and methods
Patients with an inherited bleeding disorder who underwent non-orthopaedic
general surgery between 2008 and 2012 were identiﬁed from the CCC records
within the Belfast Health and Social Care Trust (BHSCT). Patients undergoing
routine endoscopy procedures were excluded. Patients with haemophilia, VWD
and platelet disorders were included. The case notes of these patients were
examined.
3. Results
Twenty eight patients (a total of 29 procedures) were identiﬁed
who had undergone surgery during the speciﬁed period in the NI CCC
(Table 3). Twelve patients underwent general surgical procedures, 9
had vascular surgery and 7 patients underwent ENT/maxillofacial
procedures. The cohort of patients comprised 17 patients with hae-
mophilia, 9 with VWD and two with a primary platelet disorder. All
patients undergoing elective surgery were seen by a consultant
haematologist prior to referral to the surgeons. The surgical episodeTable 1
Haemophilia and related bleeding disorders in Northern Ireland.
Bleeding disorder Known affected adults (>16 years)
patients in N Ireland (n 280)
Haemophilia A 157
Haemophilia B 13
Von Willebrand Disease 92
Platelet disorders 7
Other factor deﬁciencies 11was led by the haematology team. The surgical teamwas informed of
the patient’s condition and the risk of bleeding and infection status
(vCJD, Hepatitis C, HIV) and a written management protocol was
produced for individual patients.
A speciﬁc bleeding diathesis management protocol was devised
for individual patients (see components of the protocol in discus-
sion). Local or regional anaesthesia, intramuscular injections,
aspirin, warfarin, non-steroidal anti-inﬂammatory drugs (NSAIDs)
and low molecular weight heparin for deep vein thrombosis (DVT)
prophylaxis were avoided. Instead, patients were advised on
mechanical thromboprophylaxis and given early mobilisation for
VTE prophylaxis.
Four of 28 patients developed post-operative complications
including two wound infections and two bleeding complications.
The bleeding complications included a patient who developed
wound haematoma which required evacuation ten days after the
surgery. The second patient continued to bleed after ligasure hae-
morrhoidectomy and returned to theatre ten days after the surgery
for haemostasis. In both cases, a bleeding point was identiﬁed and
secured. Excessive peri-operative bleeding was not seen in either
of the patients. Neither of the patients required blood transfusion
or additional clotting factors on top of what had already been
calculated to meet their particular needs. There were no delayed
discharges. There was no mortality in this series.
4. Discussion
Following guidance in a UK National Health Service (NHS)
circular in the early 1990s,13 inherited bleeding disorders care in
the UK has been organised into 24 CCCs and 51 smaller Haemo-
philia Centres (HCs). A CCC is deﬁned as a centre with at least 40
patients with severe haemophilia that can offer the full range of
specialised health services required for the effective management
of these patients. The number of 40 was agreed at the time of
writing the NHS guideline by a group of senior haemophilia
consultants as this was deemed to be the minimum number of
patients required for a centre to develop and maintain expertise in
the management of haemophilia.14 In providing general and
specialist surgery, it is recommended that these procedures should
be performed at a centre with expertise and which provides
a comprehensive care programme. The UK treatment strategy for
VWD is based on consensus guidelines produced by the United
Kingdom Haemophilia Centre Doctors’ Organization (UKHCDO)
relating to the diagnosis and management of VWD.15
Our experience from NI highlights the importance of an effec-
tively working CCC. Effective communication and team work
between surgeon and haematologist has led to minimal morbidity
and no mortality in the surgical management of patients with
inherited bleeding disorders. This is a similar ﬁnding reported by
multiple studies in different specialities of surgery such as ortho-
paedic surgery,5,16 cardiothoracic,17 urology18 and recently liver
transplantation.19
Patients are reviewed two weeks prior to major surgery and
their weight, base line blood tests including relevant clotting factor
levels, inhibitor screen and viral screen are checked. Medication is
reviewed and, should the patient be taking NSAIDs or any herbal
medication, these are stopped as both have an anti-platelet effect
which could potentially worsen the haemorrhagic complications of
the surgery.
Elective surgery is discussed between the haematology and
surgical teams and a surgical protocol is drawn up by the haema-
tology team. This is designed to ensure that all members of the
multidisciplinary team looking after the patient are fully acquain-
ted and aware of their requirements. The surgical protocol has
several key elements:
Table 2
Haemophilia: Now and Then.
Modern
nomenclature
Historical
nomenclature
Hereditary
nature
Deﬁciency Clinical severity Management in 1960 Management in 2011
Haemophilia A Classic haemophilia
e antihaemophilic
globulin deﬁciency
X-linked recessive
males
Factor VIII Mild to severe Fresh frozen plasma
or fresh whole blood
Recombinant factor
VIII DDAVPa
Haemophilia B Christmas disease X-linked recessive
males
Factor IX Mild to moderate Fresh frozen plasma
or fresh whole blood
Recombinant factor IX
Haemophilia C Ashkenazic Jewish
haemophilia
Autosomal recessive Factor XI Mild to moderate Fresh frozen plasma
or fresh whole blood
Plasma derived factor
XI concentrate
Von Willebrand
disease
Previously believed to
have been caused by a
functional abnormality
of the capillaries.
(pseudohaemophilia)
Most commonly
autosomal dominant
male and female
Von Willebrand
factor
Variable depending
on subtype
No speciﬁc treatment Factor VIII/Von Willebrand
factor complex or DDAVP
a Desmopressin (Deamino-D-arginine vasopressin).
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a different site to the CCC, it is important to include standard
information including the patient’s full name, date of birth,
address and diagnosis. The Health and Care Number is used
rather than the patient’s hospital number. We also include theTable 3
Summary of patients managed at Belfast CCC.
Patient Diagnosis Procedure
1 41 years male Severe haemophilia A Repair of popliteal ar
pseudo-aneurysm
2 72 years male Mild haemophilia B Right carotid endarte
3 16 years female Obligate affected carrier
of haemophilia A
Laparoscopic append
4 61 years male VWD type 2A Ligasure haemorrhoid
5 29 years female VWD type 1 Laparoscopic cholecy
6 29 years female VWD type 1 Excision supratentori
neurocytoma
7 61 years male VWD type 2A Defunctioning ileosto
8 61 years male VWD type 2A Reversal of ileostomy
9 43 years male Mild haemophilia A Laparoscopic cholecy
for cholecystitis
10 45 years female Symptomatic carrier of
haemophilia B
Laparoscopic cholecy
for biliary colic
11 63 years male VWD type 2A Right inguinal hernia
12 33 years male Haemophilia A Right inguinal hernia
13 42 years male VWD type 2A Paraumblical hernia r
14 57 years female Haemophilia A affected
carrier
Excision of sebaceous
15 42 years female VWD type 2N Varicose veins surger
16 39 years male Severe haemophilia A
with inhibitor
Insertion of Portacath
17 37 years femalea Obligate affected carrier
haemophilia A
Partial thyroidectomy
neck dissection
18 50 years male Severe haemophilia A Insertion of Portacath
19 50 years male Severe haemophilia A Removal of portacath
Hickman line
20 48 years male Mild haemophilia A
FVIII
Right leg varicose vei
21 42 years female Hermansky Pudlak
syndrome
Excision of submandi
22 34 years femalea Obligate affected carrier
haemophilia A
Partial thyroidectomy
dissection
23 52 years male Mild haemophilia A Laparoscopic cholecy
and exploration of CB
24 49 years male Severe haemophilia A Insertion Hickman lin
25 62 years male Mild haemophilia A Left carotid endartere
26 72 years female VWD type 2A Laparoscopic cholecy
27 35 years male Mild haemophilia A Excision cholesteatom
28 26 years male Bernard Soullier syndrome Excision right suprac
lymph node
a Both patients required further surgery due to persistently positive disease followingblood group and any relevant known antibodies which may
complicate the cross match.
 Category Three Status. Whilst the population of patients
with inherited bleeding disorders who have been infected
historically with hepatitis and HIV is not expanding,20 thisComplications Management of complication
tery Wound cellulitis 4 weeks
post op
Conservative with antibiotics
rectomy Continued ooze from
neck wound
Evacuation of haematoma
post op day 10
icectomy Pelvic collection Conservative management
ectomy Continued rectal bleeding
till post
op day 10
Examination under anaesthesia
and haemostasis
stectomy None
al None
my None
None
stectomy None
stectomy None
repair None
repair None
epair None
cyst None
y None
None
and None
None
/insertion None
ns surgery None
bular gland None
and neck None
stectomy
D
None
e None
ctomy None
stectomy None
a None
lavicular None
high dose iodine.
J. Ahmad et al. / International Journal of Surgery 11 (2013) 22e26 25
REVIEWinformation is essential for all healthcare professionals. More
recently, the main area of focus has been patient’s vCJD
status.21 It is important that the theatre and infection control
teams are aware of patients deemed to be a public health risk
for vCJD and protective precautions and disposable instru-
ments are used where appropriate.
 Type of surgery. The haematology team should be made fully
aware of the exact nature of the surgery, its duration and ex-
pected blood loss in a patient with a similar pathology but
without the bleeding disorder, so that appropriate amount of
factor replacement can be calculated. Surgical instrument
management for those deemed to be a public health risk for
vCJD should be discussed to avoid unnecessary quarantining.
 Pre-operative management. The detail of necessary clotting
factor replacement is provided including its type, dose, timing
and who will infuse the factors in the pre and post-operative
period. The type of factor VIII administered is important as
this dictates the type of laboratory test (one stage or two stage
clotting assay) used to check plasma levels post-infusion. In
addition, certain Factor VIII gene mutations that cause hae-
mophilia A result in discrepancies between assays requiring
that patients should be genotyped. To achieve haemostasis for
major surgical procedures in haemophilia, the aim is to achieve
an initial plasma factor VIII level of 60e100 IU/dL. For VWD,
a plasma VWF activity of around 100 IU/dL is required in the
perioperative period with the level maintained at greater than
50 IU/dL in the postoperative period. For patients with mild
haemophilia A and type 1 VWD, a documented response to
DDAVP should be obtained ahead of the planned surgery. This
level is checked and conﬁrmed prior to the surgery. Infusion of
clotting factor and checks on plasma clotting factor level are
provided by a specialist haematology nurse who remains
available for the entire surgical episode.
In general, clotting factor VIII and factor IX concentrates are
given as an initial bolus followed by a continuous infusion. Infu-
sion of factor VIII concentrate at a dose of 2e4 U/kg/h canmaintain
stable plasma levels but it is important to re-check the level
throughout the surgery and in the immediate postoperative
period as the rate of consumption may be increased if additional
blood loss occurs. Continuous infusion offers the advantage of
consistent levels, less frequent monitoring, and decreased factor
utilization. A similar effect has been noted with factor IX
concentrates. Antiﬁbrinolytic therapy may be indicated alongside
factor replacement to further reduce the risk of haemorrhage.
Other treatment options, depending on the surgery and the
patient’s underlying bleeding disorder, include desmopressin,
Von Willebrand factor concentrate, or activated recombinant
factor VII. Regional anaesthesia is relatively contraindicated even
with factor concentrate administration. Regional anaesthesia may
be offered to some patients with extensive comorbid conditions.
However, this would only be undertaken with onsite access to
a haematology laboratory as factor levels need to be checked
throughout the surgery. This would not be required if the patient
receives general anaesthesia.
Clotting factor levels should not exceed the limits stated above
due to an increased risk of venous thrombosis.
 Peri-operative management. This section contains all the emer-
gency telephone numbers for contact if excessive bleeding is
encountered. The haematology registrar and consultant are
available out of hours for emergency consults. It also highlights
whether further concentrates are required to be given during
the surgery. This tends to occur if the surgery is expected to
exceed 4 h. Post-operative management. If required, factor levels are
advised to be checked at the time of completion of the surgery.
Blood is taken from a peripheral vein and every effort is made
to ensure the sample is free from heparin contamination. A
clotting factor level of 100% is the aim. The rate of consumption
of clotting factors is greatest within the ﬁrst two to three days
after the surgery, the dose required and levels are reduced
thereafter. The checking of the levels and their frequency are
highlighted. Further to the surgery, if physiotherapy is antici-
pated, directions are given as to when this should be safely
undertaken e generally within the ﬁrst few hours of the
morning dose of concentrate, ensuring the level is at its peak.
 Discharge advice. Frequently, patients recover from their
surgery sooner than the replacement factor therapy can be
stopped. The patients are discharged at the discretion of the
surgical team22 and the haematology team is advised regarding
the timing of surgical clips removal (if used) so that adequate
factors level could be ensured. Further to discharge, on-going
factor replacement programme is continued either through
the CCC or via local hospitals, a link for which has been long
established and works seamlessly. All patients are reviewed
weekly within the CCC for three weeks after the operation,
followed by routine review.
5. Conclusions
Our patients with inherited bleeding disorders undergoing non-
orthopaedic surgery had low incidence of complications with no
additional factors or treatment required over and above the amount
stipulated in the protocol devised prior to surgery. No patient
required blood transfusion. There was no mortality in this series.
Surgery in patients with inherited bleeding disorders has become
safer with the advent of multidisciplinary CCCs. Close communi-
cation between surgeon and haematologist is the key to successful
management of these patients.
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